United States - English - NLM (National Library of Medicine)

apotex corp. - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - azelastine hydrochloride 0.5 mg in 1 ml - azelastine hydrochloride ophthalmic solution is indicated for the treatment of itching of the eye associated with allergic conjunctivitis. azelastine hydrochloride ophthalmic solution is contraindicated in persons with known or suspected hypersensitivity to any of its components.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pregabalin, quantity: 300 mg - capsule, hard - excipient ingredients: lactose monohydrate; pregelatinised maize starch; titanium dioxide; iron oxide yellow; purified talc; gelatin; iron oxide red; iron oxide black; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; potassium hydroxide - pregabalin apotex is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation pregabalin apotex is indicated for the treatment of neuropathic pain in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pregabalin, quantity: 150 mg - capsule, hard - excipient ingredients: lactose monohydrate; pregelatinised maize starch; titanium dioxide; iron oxide black; purified talc; gelatin; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; potassium hydroxide - pregabalin apotex is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation pregabalin apotex is indicated for the treatment of neuropathic pain in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pregabalin, quantity: 75 mg - capsule, hard - excipient ingredients: lactose monohydrate; pregelatinised maize starch; titanium dioxide; iron oxide red; purified talc; gelatin; iron oxide yellow; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - pregabalin apotex is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation pregabalin apotex is indicated for the treatment of neuropathic pain in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pregabalin, quantity: 25 mg - capsule, hard - excipient ingredients: lactose monohydrate; pregelatinised maize starch; titanium dioxide; iron oxide black; purified talc; gelatin; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; potassium hydroxide - pregabalin apotex is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation pregabalin apotex is indicated for the treatment of neuropathic pain in adults.

Ireland - English - HPRA (Health Products Regulatory Authority)

apotex europe b.v. - rasagiline mesilate - tablets - 1 milligram - rasagiline

United States - English - NLM (National Library of Medicine)

apotex corp. - clorazepate dipotassium (unii: 63fn7g03xy) (clorazepic acid - unii:d51wo0g0l4) - clorazepate dipotassium tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. the effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. long-term studies in epileptic patients, however, have shown continued therapeutic activity. the physician should reassess periodically the usefulness of the drug for the individual patient. clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. clorazepate dipotassium tablets are contraindicated in patients with a known hypersensitivity to the drug and in those with acute narrow angle glaucoma. controlled substance clorazepate dipot

United States - English - NLM (National Library of Medicine)

apotex corp. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel should be administered in conjunction with aspirin. - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are contrai

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - montelukast sodium 4.16mg equivalent to 4 mg motelukast - chewable tablet - 4 mg - active: montelukast sodium 4.16mg equivalent to 4 mg motelukast excipient: aspartame cherry flavour 501027 ap0551 croscarmellose sodium iron oxide red magnesium stearate mannitol microcrystalline cellulose - apo-montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - montelukast sodium 5.2mg equivalent to 5 mg montelukast - chewable tablet - 5 mg - active: montelukast sodium 5.2mg equivalent to 5 mg montelukast excipient: aspartame cherry flavour 501027 ap0551 croscarmellose sodium iron oxide red magnesium stearate mannitol microcrystalline cellulose - apo-montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm.